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Ameliorating Skin-Homing Receptors on
Malignant T Cells with a Fluorosugar Analog
of N-acetylglucosamine: P-Selectin Ligand
Is a More Sensitive Target than E-Selectin Ligand
Leyla Descheny1, Madeliene E. Gainers1,2, Bruce Walcheck3 and Charles J. Dimitroff1,2
Expression of E- and P-selectin ligands is required for T cell entry into skin. Sialyl Lewis X moieties are critical
for ligand activity and are elevated on malignant skin-homing T cells. We hypothesize that these glycosylations
are selectable targets for treating the dermal tropism associated with cutaneous lymphomas. In this study, we
analyzed the efficacy of a novel 4-fluorinated analog of N-acetylglucosamine (GlcNAc) on E- and P-selectin
ligands expressed by malignant skin-homing T cells. We also examined the specificity of 4-F-GlcNAc
(2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose) action by contrasting the effects on sialyl
Lewis X expression displayed by P-selectin glycoprotein ligand-1 (PSGL-1) with sialylated O-glycans expressed
by CD43. Using parallel-plate flow analysis, we found that 4-F-GlcNAc elicited 5-fold more potent inhibition
on P-selectin ligand activity than on E-selectin ligand activity. To determine whether glycosylations conferring
E- and P-selectin ligand activities were inhibited, we analyzed the expression of sialyl Lewis X and
sialyl-fucosylated core 2 O-glycan (CHO-131 antigen), respectively. We found that 4-F-GlcNAc treatment
resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1, whereas
sialylated O-glycans on CD43 were minimally affected. These results indicate that 4-F-GlcNAc treatment
can selectively downregulate the P-selectin ligand activity and potentially prevent dermal dissemination
of cutaneous lymphomas.
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INTRODUCTION
Sialyl Lewis X moieties, defined by a2,3 sialylated and
a1,3 fucosylated N-acetyllactosamine, are characteristically
expressed on skin-homing T cells and are necessary for
T cell trafficking to skin (Picker et al., 1990; Berg et al., 1991).
Detection of this moiety with the anti-sialyl Lewis X mAb
HECA-452 confers a skin-tropic phenotype of T cells and is
characteristically displayed on P-selectin glycoprotein ligand-1
(PSGL-1), otherwise known as cutaneous lymphocyte-
associated antigen (CLA) (Fuhlbrigge et al., 1997). Expression
of HECA-452 antigen and another sialyl Lewis X epitope
recognized by newly described mAb, CHO-131, directly
correlates with the capacity of PSGL-1 to interact with dermal
endothelial E- and P-selectin, respectively (Fuhlbrigge et al.,
2002; Walcheck et al., 2002). These Ca2þ -dependent,
vascular endothelial receptors mediate tethering and rolling
of T cells on dermal microvessel surfaces, initiating recruit-
ment into skin for the maintenance of immune surveillance or
pathologic inflammatory processes (Davis and Smoller, 1992;
Rossiter et al., 1994; Robert and Kupper, 1999). Notably,
CLA is conspicuously upregulated on malignant T cells in
patients with cutaneous T cell lymphoma (CTCL) and directly
correlates with the unique pattern of skin involvement,
providing the opportunity to target these sialyl Lewis X
moieties and attenuate the dermal dissemination of malignant
T cells (Borowitz et al., 1993; Robert and Kupper, 1999;
Ferenczi et al., 2002; Yamaguchi et al., 2003).
Mice deficient in endothelial E- and P-selectin (Staite
et al., 1996; Catalina et al., 1999; Smithson et al., 2001;
Hirata et al., 2002) or in a1,3 fucosyltransferase VII (Smithson
et al., 2001; Erdmann et al., 2002), which fucosylates PSGL-
1, exhibit defective cutaneous inflammatory responses,
providing pharmacologic rationale for investigating strategies
to prevent dermal dissemination of malignant T cells. We
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have previously shown that a novel N-acetylglucosamine
(GlcNAc) sugar substituted with a fluorine atom at the
carbon-4 position, named 4-F-GlcNAc (2-acetamido-1,3,6-
tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose), can block
the synthesis of N-acetyllactosamine structures, thereby inhi-
biting sialyl Lewis X expression and selectin ligand activity
(Woynarowska et al., 1996). In particular, 4-F-GlcNAc down-
regulates CLA expression on ex vivo-cultured human CLAþ T
cells by incorporating into PSGL-1 O-glycans and preventing
the synthesis of sialyl Lewis X (Dimitroff et al., 2003a).
Using an in vivo model of allergic contact dermatitis that is
dependent on effector T cell E- and P-selectin ligand
expression, we demonstrate that 4-GlcNAc prevents T cell
E-selectin ligand expression and T cell-mediated inflamma-
tion (Dimitroff et al., 2003b). Whereas other carbohy-
drate-dependent processes required for antigen-dependent
inflammation, such as naı¨ve lymphocyte homing to lymph
nodes and dendritic cell migration into lymph nodes, do not
appear to be affected by 4-F-GlcNAc (Dimitroff et al.,
2003b). These effects on CLA expression and function have
heightened our enthusiasm for potentially controlling the
pathogenesis of cutaneous lymphomas.
In this report, we examined the efficacy and potency of
4-F-GlcNAc on E- and P-selectin ligand activity displayed by
malignant human CLAþ Hut 78 T cells derived from a patient
with CTCL. We also investigated the modulation of sialyl
Lewis X epitopes, HECA-452 antigen, and CHO-131 antigen,
which directly correspond to E- and P-selectin ligand activity
on PSGL-1. The specificity of 4-F-GlcNAc anticarbohydrate
action was also explored by elucidating 4-F-GlcNAc efficacy
on sialylated O-glycans expressed by CD43. Compared with
HECA-452 antigen and E-selectin ligand inhibition, CHO-131
antigen and P-selectin ligand activity of PSGL-1 were 5-fold
more sensitive to 4-F-GlcNAc treatment. Of note, sialyl Lewis
X epitopes and E-selectin ligand activity on glycolipid scaffolds,
which represents B50% of total cellular activity, were
unaffected by 4-F-GlcNAc treatment, and 4-F-GlcNAc efficacy
on CD43 sialylated O-glycans was insignificant. Mechanisti-
cally, formation of the N-acetyllactosamine corresponding to
CHO-131 antigen and P-selectin ligand at the N-terminus of
PSGL-1 was particularly sensitive to 4-F-GlcNAc treatment.
These findings indicate that E- and P-selectin-binding determi-
nants could be opportune targets for controlling the dermal
dissemination of malignant skin-homing T cells.
RESULTS
We have previously shown that 4-F-GlcNAc can modulate
E- and P- selectin ligand activities on ex vivo cultures of normal
CLAþ T cells (Dimitroff et al., 2003a). Since E- and P-selectin
ligand activities on T cells confer a skin-tropic phenotype, we
believe that these ligand activities are targetable entities
for controlling the dermal tropism associated with T cell-
mediated inflammation and cancer. With regard to CTCL,
there is strong evidence indicating that CLA is upregulated on
malignant T cells and is associated with cutaneous involve-
ment and progression of CTCL (Borowitz et al., 1993; Heald
et al., 1993; Robert and Kupper, 1999; Ferenczi et al., 2002).
As T cell E-selectin ligand activity is directly related with CLA
expression (Fuhlbrigge et al., 1997) and a subset of CLAþ
T cells bind P-selectin (Walcheck et al., 2002; and Ni Z,
Campbell JJ, G. Niehans G, Walcheck B. CHO-131 reactivity
with human T cells corresponds with a high P-selectin
binding activity. Manuscript submitted for publication),
we hypothesize that the association between elevated
CLA expression and CTCL progression is owing to concomi-
tant elevations in P- and E-selectin ligand activities on
malignant T cells.
In the following analyses, we determined the sensitivity
and specificity of 4-F-GlcNAc efficacy on E- and P-selectin
carbohydrate recognition determinants relative to effects on
other glycoconjugates expressed by malignant human T cells.
We utilized Hut 78 cells, which are malignant CD4þ T cells
derived from a patient with Sezary syndrome, as a malignant
T cell model for biochemical and antiadhesion analysis of
4-F-GlcNAc efficacy (Gazdar et al., 1980). Before incuba-
tions in 4-F-GlcNAc and other control glycosylation inhibi-
tors, we assessed treatments on Hut 78 cultures in log phase
growth to determine pertinent concentrations for analysis of
glycan and adhesion modulation. We found that 4-F-GlcNAc
concentrations less than 0.15 mM (oIC10) did not affect
T cell growth and did not affect the expression of T cell
marker CD4 and of PSGL-1 (data not shown). Benzyl-O-
N-acetylgalactosamide (BAG), a metabolic inhibitor of
O-glycan biosynthesis, was tested at concentrations
previously shown to inhibit sialyl Lewis X and/or O-glycan
expression and did not affect cell growth and protein
synthesis (data not shown) (Dimitroff et al., 2003a).
4-F-GlcNAc efficacy on E- and P-selectin ligand expression on
malignant T cells
Using the parallel-plate flow chamber under physiologic
shear forces, we examined the capacity of Hut 78 cells
treated with 4-F-GlcNAc to bind E- and P-selectin. As
expected, control neuraminidase treatment completely abro-
gated both E- and P-selectin ligand activities on Hut 78 cells
(Figure 1). However, while E-selectin ligand activity was
significantly diminished in a dose-dependent manner from 10
to 100mM 4-F-GlcNAc, only a maximal 50% inhibition of
untreated control was observed at the highest dose (statisti-
cally significant difference compared with untreated control;
Po0.001) (Figure 1). Likewise, protease (bromelain) treat-
ment and BAG treatments exhibited a maximal reduction
of E-selectin ligand activity by 50% (Figure 1). These results
suggested that a residual E-selectin ligand activity was
mediated by sialylated glycolipid and that 4-F-GlcNAc only
affects E-selectin-binding determinants on glycoprotein.
On the contrary, we found that 4-F-GlcNAc caused a more
potent dose-dependent reduction in P-selectin ligand activity,
in which the lowest dose of 10mM resulted in a significant
reduction by 44% and the highest dose at 100mM eliminated
activity (statistically significant difference compared with
untreated control) (Figure 1). Removal of O-glycans and
membrane protein by BAG (2 mM) and bromelain treatments,
respectively, similarly eliminated P-selectin ligand activity
(Figure 1), confirming PSGL-1’s role as the principal T cell
P-selectin ligand (Vachino et al., 1995).
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Complementary experiments were conducted using flow
cytometry with mAbs HECA-452 and CHO-131 to determine
whether sialyl Lewis X (HECA-452 antigen) and/or sialyl-
fucosylated core 2 O-glycans (CHO-131 antigen) were
downregulated following 4-F-GlcNAc treatment. Expression
of HECA-452 and CHO-131 antigen confers the presence of
carbohydrate recognition determinants on T cells for binding
to E- and P-selectin, respectively (Walcheck et al., 2002).
Using Hut 78 cells treated identically to cells used in cell
rolling experiments, we found that neuraminidase treatment
caused marked reductions in both HECA-452 and CHO-131
antigen levels, whereas control phosphate-buffered saline
(PBS)-treated cells and control GlcNAc-treated cells showed
no change in antigen levels (Figure 2a and b). We found that
4-F-GlcNAc inhibited both HECA-452 and CHO-131 antigen
expression, but as observed in cell-binding experiments,
10 mM 4-F-GlcNAc resulted in a 35% reduction in CHO-131
antigen expression, while having no effect on HECA-452
antigen at 10 mM (Figure 2a and b). Interestingly, HECA-452
antigen levels were not completely removed at the highest
concentrations of BAG and 4-F-GlcNAc, and protease bro-
melain treatment only halved HECA-452 antigen expression
(Figure 2a). On the contrary, 100mM 4-F-GlcNAc, 2 mM BAG,
and protease showed markedly lower levels of CHO-131
antigen compared with PBS diluent controls (Figure 2b). With
the exception of protease treatment, expression of PSGL-1
polypeptide was not lowered after neuraminidase, GlcNAc,
BAG, or 4-F-GlcNAc treatments, suggesting that expression
of candidate selectin glycoprotein scaffolds were not affected
(Figure 2c). These data corroborated with cell rolling data
and showed that CHO-131 antigen was likely presented by
PSGL-1 and directly correlated with P-selectin ligand activity
and that HECA-452 antigen was expressed on both glyco-
protein and glycolipid and directly correlated with E-selectin
ligand activity.
4-F-GlcNAc efficacy on sialyl Lewis X and sialyl-fucosylated
core 2 O-glycans displayed by PSGL-1
To investigate 4-F-GlcNAc efficacy on the expression of sialyl
Lewis X and sialyl-fucosylated core 2 O-glycans displayed on
glycoprotein(s), we immunoblotted lysates from 4-F-GlcNAc-
treated Hut 78 cells with mAb HECA-452 or mAb CHO-131,
respectively. MAb HECA-452- and CHO-131-reactive glyco-
protein(s), principally detected at 120 and 240 kDa in lysates
from untreated (PBS) Hut 78 cells, was completely eliminated
following neuraminidase or BAG treatments (Figure 3a).
Furthermore, treatment with 4-F-GlcNAc elicited a dose-
dependent decrement in HECA-452 and CHO-131 antigen
on glycoprotein with complete disappearance at 100mM,
a 20-fold lower concentration than BAG (Figure 3a and b).
Moreover, densitometric analysis of CHO-131 staining of
glycoprotein from cells treated with 10 mM 4-F-GlcNAc
revealed a significant diminution compared with PBS
control (Po0.01; Student’s paired t-test) (Figure 3b). Note
that molecular control, GlcNAc, had no effect on antigen
expression and that equivalent levels of b-actin were detected
in immunoblots from lysates displaying low to nil levels of
HECA-452 and CHO-131 antigen, suggesting that reductions
in sialyl Lewis X and in sialyl-fucosylated core 2 O-glycans
were independent of protein synthesis (Figure 3a and b).
To examine directly the effects of 4-F-GlcNAc on
candidate E- and P-selectin glycoprotein ligand at 120 and
240 kDa, we immunoprecipitated PSGL-1 with mAb KPL-1
and blotted with mAb HECA-452, mAb CHO-131, E-selectin-
Ig chimera, or mAb KPL-1. As PSGL-1 characteristically
resolves at B120 and 240 kDa and is a major glycoprotein
on T cells that displays HECA-452 antigen and E-selectin-
binding determinants (Borges et al., 1997; Fuhlbrigge et al.,
1997, 2002; Dimitroff et al., 2003a), we presumed that
PSGL-1 was the major glycoprotein bearing E- and P-selectin
carbohydrate recognition determinants on Hut 78 cells. As
shown in the anti-PSGL-1 immunoblot, PSGL-1 was present
at comparable levels in immunoprecipitates from all treated
cells and isotype Ab control immunoprecipitates did not
contain any PSGL-1 (Figure 4a). Compared with staining of
anti-PSGL-1 immunoprecipitates from PBS- or GlcNAc-
treated cells, neuraminidase and BAG treatments significantly
reduced HECA-452 and CHO-131 antigen and E-selectin-
binding determinants on PSGL-1 (Po0.01; Student’s paired
t-test) (Figure 4a and b). 4-F-GlcNAc treatments resulted in a
dose-dependent reduction in HECA-452 and CHO-131
antigen and E-selectin ligand on PSGL-1 (Figure 4a and b).
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Figure 1. Parallel-plate flow analysis of 4-F-GlcNAc efficacy on malignant
T cell E- and P-selectin ligand activities. At 2.0 Dyn/cm2, we analyzed the
rolling activity of Hut 78 cells treated with neuraminidase, protease
(bromelain), 1 mM GlcNAc, 2 mM BAG, or 10, 50 or 100 mM 4-F-GlcNAc.
Mean cell rolling (SEM) frequencies on immobilized human E- or P-selectin
chimera were quantified from a minimum of three fields, and experiments
were repeated a minimum of three times. Cell rolling on human IgG or in
assays performed in the presence of 5 mM EDTA was not evident. (*Po0.001;
statistically significant difference compared with untreated control, Student’s
paired t-test).
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Notably, 4-F-GlcNAc markedly inhibited CHO-131 antigen,
which directly corresponds to P-selectin ligand activity, on
PSGL-1 at 10 mM, whereas 10 mM 4-F-GlcNAc did not greatly
affect HECA-454 antigen and E-selectin ligand levels on
PSGL-1 (Figure 4a and b). As CHO-131 antigen directly
corresponds to P-selectin ligand expression (Walcheck et al.,
2002), P-selectin ligand activity appeared to be more
sensitive to 4-F-GlcNAc treatment than E-selectin-binding
determinants on PSGL-1.
To investigate the selectivity of 4-F-GlcNAc efficacy on
endothelial selectin recognition determinants, we analyzed
the expression of sialylated O-glycans on T cell sialomucin,
CD43, following 4-F-GlcNAc treatment. CD43 characteristi-
cally expresses high levels of sialylated O-glycans (Piller
et al., 1988; Mukasa et al., 1999), serving as an analogous
counterpart to PSGL-1 for the assessment of 4-F-GlcNAc’s
effects on glycosylations expressed by an O-glycosylated
glycoprotein in the same cell. We immunoblotted lysates
from treated Hut 78 cells with mAb L60, which recognizes
sialylated O-glycan epitopes on CD43 (Ardman et al., 1992;
Dimitroff et al., 2003a). As expected, neuraminidase and
BAG treatments completely eliminated mAb L60 reactivity of
CD43 (Figure 5a). However, 4-F-GlcNAc, even at 100 mM, did
not significantly lower sialylated O-glycans on CD43 ((Figure
5a and b). The resistance of CD43 to 4-F-GlcNAc modulation
prompted further scrutiny on the type of O-glycans displayed
by CD43. To determine whether CD43 expresses sialyl-
fucosylated core 2 O-glycans, we immunoprecipitated CD43
with anti-CD43 mAb 1G10 from Hut 78 cell lysates and then
blotted with mAb CHO-131. Immunoblotting of anti-CD43
1G10 immunoprecipitates with mAbs 1G10 and L60 was
performed in parallel to control for presence of sialo-O-
glycosylated CD43 in anti-CD43 mAb 1G10 immunopreci-
pitates. Anti-CD43 immunoprecipitation of neuraminidase-
treated cell lysates blotted with mAb L60 was also conducted
to validate sialic acid-dependent reactivity of mAb L60. We
found that while CD43 was detected in anti-CD43 immuno-
precipitates blotted with mAb 1G10 and mAb L60, CHO-131
antigen was not present on CD43.
DISCUSSION
E- and P-selectin-binding determinants have been implicated
as potential targets in the treatment of T cell-mediated
cutaneous inflammation. We have shown that a fluorinated
sugar analog of N-acetylglucosamine, otherwise known as
4-F-GlcNAc, functions as a potent metabolic inhibitor of
N-acetyllactosamine and sialyl Lewis X biosynthesis. After
passive cellular uptake and conversion to UDP-4-F-GlcNAc,
the fluorine at carbon-4 of 4-F-GlcNAc appears to block
subsequent addition of nucleotide sugar, UDP-Gal (Bernacki
et al., 1977; Sharma et al., 1990; Woynarowska et al., 1996;
Dimitroff et al., 2003a). Prior studies provide evidence that
this mechanism of action results in the inhibition of E- and
P-selectin ligand biosynthesis on normal human CLAþ T cells
and on effector lymphocytes involved in antigen-dependent
cutaneous inflammation (Dimitroff et al., 2003a, b). Specifi-
cally, E-selectin-binding determinants on PSGL-1 (i.e. CLA)
are downregulated on ex vivo-cultured human CLAþ T cells
MCF = 498
MCF = 67
MCF = 920
MCF = 1255
MCF = 185
MCF = 963
MCF = 199
MCF = 176
PBS
Neuraminidase
Protease
Negative drug control
GlcNAc
(1 mM)
Benzyl-O-GalNAc
(2 mM)
4-F-GlcNAc
(10 M)
4-F-GlcNAc
(50 M)
4-F-GlcNAc
(100 M)
PBS
Neuraminidase
Protease
Negative drug control
GlcNAc
(1 mM)
Benzyl-O-GalNAc
(2 mM)
4-F-GlcNAc
(10 M)
4-F-GlcNAc
(50 M)
4-F-GlcNAc
(100 M)
PBS
Neuraminidase
Protease
Negative drug control
GlcNAc
(1 mM)
Benzyl-O-GalNAc
(2 mM)
4-F-GlcNAc
(10 M)
4-F-GlcNAc
(50 M)
4-F-GlcNAc
(100 M)
75%
3%
2%
68%
49%
21%
17%
1%
MCF = 16
MCF = 81
MCF = 95
MCF = 67
MCF = 65
MCF = 87
MCF = 70
MCF = 100
M1
M1
M1
M1
M1
M1
M1
M1 M1
M1
M1
M1
M1
M1
M1
M1 M1
M1
M1
M1
M1
M1
M1
M1
a b c
Figure 2. Flow cytometric analysis of HECA-452 and CHO-131 antigen and of PSGL-1 expression on malignant T cells treated with 4-F-GlcNAc. Hut 78
cells treated with neuraminidase, protease (bromelain), 1 mM GlcNAc, 2 mM BAG, or 10, 50, or 100mM 4-F-GlcNAc were stained with (a) mAb HECA-452,
(b) mAb CHO-131, or (c) anti-PSGL-1 mAb PL-2 and respective fluorochrome-conjugated secondary Ab. Data in (a) and (c) are presented as MCF of
positive stained cells, whereas data in (b) are presented as % positive stained cells. Experiments were repeated a minimum of three times. MCF¼mean
channel fluorescence.
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owing to the direct incorporation of 4-F-GlcNAc into PSGL-1
O-glycans (Dimitroff et al., 2003a). As CLA expression is
associated with the progression of cutaneous lymphomas, we
hypothesized that CLA modulation could be an attractive
approach for altering the pathogenesis of cutaneous lympho-
mas by preventing the dermal tropism of malignant T cells.
Assaying E-selectin-binding determinants on T cell PSGL-1
with mAb HECA-452 has previously been employed for the
analysis of 4-F-GlcNAc efficacy. As sialyl Lewis X on PSGL-1
O-glycans also corresponds to P-selectin ligand activity,
we have speculated that reductions in HECA-452 antigen
expression also reasoned for P-selectin ligand down-
regulation caused by 4-F-GlcNAc (Dimitroff et al.,
2003a). However, a recent description of mAb CHO-131,
which specifically binds a core 2 O-glycan with a single
N-acetyllactosamine unit terminated by sialyl Lewis X,
suggests that CHO-131 antigen directly correlates with
P-selectin ligand expression and is found on only a subset
of HECA-452þ T cells (Walcheck et al., 2002). This
evidence, therefore, suggests that CHO-131 antigen may be a
more suitable marker for analysis of 4-F-GlcNAc efficacy of
P-selectin ligand activity. In this report, we analyzed the
efficacy and selectivity of 4-F-GlcNAc treatment on E- and
P-selectin ligand activities expressed by malignant CLAþ
T cells. We also examined the expression of HECA-452 and
CHO-131 antigen on PSGL-1 to determine whether E- and
P-selectin-binding determinants were differentially inhibited
by 4-F-GlcNAc treatment. Effects on sialylated O-glycosyla-
tions expressed by CD43 were also assayed to elucidate the
selectively of 4-F-GlcNAc on other heavily O-glycosylated
glycoproteins.
Using malignant human CD4 and CLAþ Hut 78 T cells as
a model system and non-growth inhibitory concentrations of
4-F-GlcNAc and other control glycosylation treatments,
we found that 4-F-GlcNAc exhibited disparate inhibitory
potencies on E- and P-selectin ligand activities. E-selectin-
binding determinants on Hut 78 cells displayed by the major
glycoprotein carrier PSGL-1 were notably downregulated
with 50 mM 4-F-GlcNAc, whereas expression of HECA-452
antigen and E-selectin-binding determinants on glycolipid
were unaffected. As a result, Hut 78 cellular E-selectin ligand
activity was inhibited maximally by 50% of untreated control
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Figure 3. Western blot analysis. HECA-452 and CHO-131 antigen expression
on glycoprotein expressed by malignant T cells treated with 4-F-GlcNAc. In
(a), lysates (20mg/lane) from Hut 78 cells treated with diluent control,
neuraminidase, 1 mM GlcNAc, 2 mM BAG, or 10, 50, or 100mM 4-F-GlcNAc
were resolved on reducing 4–20% SDS-PAGE gradient gels and immuno-
blotted with mAbs HECA-452, CHO-131, or anti-b-actin. In (b), densitometric
analysis of HECA-452 and CHO-131 immunostained protein from 250 to
100 kDa and of anti-b-actin-stained protein at 42 kDa was performed using
NIH ImageJ software. Mean gray scale units were normalized to background
staining intensities and averaged from a minimum of three experiments.
(*Po0.01; statistically significant difference compared with PBS control,
Student’s paired t-test).
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Figure 4. Western blot analysis. HECA-452, CHO-131, and E-selectin ligand
expression on PSGL-1 immunoprecipitated from malignant T cells treated
with 4-F-GlcNAc. In (a), lysates (100 mg) from Hut 78 cells treated with diluent
control, neuraminidase, 1 mM GlcNAc, 2 mM BAG, or 10, 50, or 100 mM
4-F-GlcNAc were immunoprecipitated with anti-PSGL-1 mAb KPL-1 or
isotype IgG control. Immunoprecipitates were resolved on reducing 4–20%
SDS-PAGE gradient gels and immunoblotted with mAb HECA-452,
E-selectin-Ig, mAb CHO-131, or mAb KPL-1. In (b), densitometric analysis of
HECA-452, E-selectin-Ig, CHO-131, and KPL-1 immunostained protein from
250 to 100 kDa was performed using NIH ImageJ software. Mean gray
scale units were normalized to background staining intensities and averaged
from a minimum of three experiments. (*Po0.01; statistically significant
difference compared with PBS control, Student’s paired t-test).
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following 4-F-GlcNAc treatment. This moderate reduction in
cellular E-selectin ligand activity corroborates with prior data
on the resistance of E-selectin glycolipid ligand on normal
CLAþ T cells to 4-F-GlcNAc treatment (Dimitroff et al.,
2003a). Interestingly, a recent report suggests that a large
percentage CLAþ T cells also express sialyl 6-sulfo Lewis X,
which may be correlative with T cell resistance to 4-F-
GlcNAc inhibitory on HECA-452 antigen and E-selectin
ligand expression (Ohmori et al., 2006). On the other hand,
4-F-GlcNAc efficacy on CHO-131 antigen and P-selectin
ligand expression was more effective, causing complete
removal of antigen/activity expression at 50 mM 4-F-GlcNAc.
Even at a 5-fold lower concentration of 10 mM, 4-F-GlcNAc
significantly blunted CHO-131 antigen on PSGL-1 and
P-selectin ligand activity.
As P-selectin carbohydrate recognition determinants
were more sensitive than E-selectin carbohydrate recogni-
tion determinants to metabolic inhibition by 4-F-GlcNAc,
we speculate that CHO-131 antigen on PSGL-1 is a more
sensitive carbohydrate moiety than HECA-452 antigen.
Whereas HECA-452 antigen may potentially be displayed
on multiple sialyl Lewis X-bearing O-glycans on PSGL-1
(Wilkins et al., 1996), CHO-131 antigen appears to be
restricted to Thr-57 of the N-terminus and P-selectin-binding
region of PSGL-1 and shown to contain sialyl Lewis X on a
single N-acetyllactosamine and not on a poly-N-acetyllacto-
samine (Liu et al., 1998; Leppanen et al., 2002; Walcheck
et al., 2002). As sialyl Lewis X moieties have been estimated
to be found largely on poly-N-acetyllactosamines on PSGL-1
(Wilkins et al., 1996), we have previously argued that
4-F-GlcNAc inhibitory efficacy on HECA-452 antigen
displayed by PSGL-1 was owing to the termination of poly-
N-acetyllactosamines on O-glycans (Dimitroff et al., 2003a).
However, the data presented here suggest that, in addition to
inhibition of poly-N-acetyllactosamines bearing HECA-452
antigen, 4-F-GlcNAc could also, and perhaps even preferen-
tially, modify CHO-131 antigen, which contains a single
GlcNAc sugar for substitution by 4-F-GlcNAc. Furthermore,
in prior studies investigating in vivo inhibitory efficacy of 4-F-
GlcNAc on E-selectin ligand expression and allergic contact
dermatitis, we may not have fully appreciated 4-F-GlcNAc
effects on P-selectin ligand expression (Dimitroff et al.,
2003b). Complementary inhibition of both E- and P-selectin
ligand activities may be responsible for the potent anti-
inflammatory effects by 4-F-GlcNAc (Dimitroff et al., 2003b).
Indeed, deletion of either E-selectin or P-selectin expression
is not sufficient to inhibit delayed-type contact hypersensi-
tivity, whereas E-/P-selectin doubly deficient mice exhibit
significantly impaired delayed-type contact hypersensitivity
responses (Staite et al., 1996). Thus, we speculate that dual
inhibitory efficacy on malignant T cell E- and P-selectin
ligand activity would need to be attained to effectively blunt
dermal tropism.
To address the selectivity of 4-F-GlcNAc inhibition on
selectin ligand biosynthesis among other O-glycosylated
membrane proteins, we analyzed the expression of sialylated
O-glycans on CD43 from 4-F-GlcNAc-treated mice. At
concentrations that downregulated CHO-131 and HECA-
452 expression on PSGL-1, 4-F-GlcNAc did not appreciably
inhibit sialylated O-glycan formation on CD43, as deter-
mined by the immunoblotting CD43 with anti-CD43 mAb
L60. Furthermore, we did not detect CHO-131 antigen on
CD43, which corroborates prior evidence showing that CD43
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Figure 5. Western blot analysis of sialylated O-glycans on CD43 expressed
by malignant T cells treated with 4-F-GlcNAc. In (a), lysates (5 mg/lane) from
Hut 78 cells treated with diluent control, neuraminidase, 1 mM GlcNAc, 2 mM
BAG, or 10, 50, or 100mM 4-F-GlcNAc were resolved on reducing 4–20%
SDS-PAGE gradient gels and immunoblotted with anti-CD43 mAb L60. In (b),
densitometric analysis of L60 immunostained protein from 200 to 100 kDa
was performed using NIH ImageJ software. Mean gray scale units (SEM) were
normalized to background staining intensities and averaged from a minimum
of three experiments. (*Po0.01; statistically significant difference compared
with PBS control, Student’s paired t-test) In (c), Hut 78 cell lysates were
immunoprecipitated with mAb 1G10 and blotted with either mAbs 1G10,
L60, or CHO-131. Mouse IgG isotype control immunoprecipitations were
performed in parallel and did not show any anti-CD43 mAb reactivity.
Experiments were repeated a minimum of three times.
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does not bind P-selectin (Moore et al., 1994; Fuhlbrigge et al.,
2006) and that CD43 O-glycans are mainly non-fucosylated
(Maemura and Fukuda, 1992). The resistance of CD43
sialylated O-glycans to 4-F-GlcNAc modulation is most likely
owing to the lower content of GlcNAc compared with
that found in PSGL-1 O-glycans. Relative to GalNAc, GlcNAc
levels in PSGL-1 O-glycans are 2-fold greater than those
found on CD43 O-glycans (Wilkins et al., 1996). Although
CD43 and PSGL-1 share similar levels of core 2 O-glycans,
generation of sialyl Lewis X conferring selectin-binding
determinants is restricted to certain membrane scaffolds that
seem to be particularly sensitive to 4-F-GlcNAc modulation.
Collectively, our results reveal that P-selectin ligand
modification on malignant T cells is sensitive to 4-F-GlcNAc
treatment. Whereas 50 mM 4-F-GlcNAc causes a 50%
decrement in P-selectin ligand activity on normal CLAþ
T cells (Dimitroff et al., 2003a), we found that a 5-fold lower
concentration of 4-F-GlcNAc inhibits P-selectin ligand
activity by 50% on malignant T cells. Whether a similar
level of 4-F-GlcNAc inhibitory efficacy can be observed on
malignant T cells in patients is still uncertain. The relative
level of E- and P- selectin ligand expression and sensitivity
of ligand biosynthesis to 4-F-GlcNAc by malignant T cells,
in vivo, has not yet been ascertained. Despite the lack of
in vivo data, we speculate that interference of CLA and
CHO-131 antigen expression will modify the skin-homing
capacity of CTCL cells and suppress the progression of CTCL.
In prospective combined treatment strategies, inhibiting the
migration of malignant T cells to skin with 4-F-GlcNAc could
help retain malignant cells in circulation, whereby other
systemic therapies, such as extracorporeal photochemother-
apy, could more effectively target circulating malignant cells.
MATERIALS AND METHODS
Cells, enzymes, and metabolic inhibitors
Human Hut 78 T cells, a malignant T cell clone with skin-homing
receptor expression from a patient with CTCL, was purchased from
ATCCs (Manassas, VA) and maintained in Iscove’s modified
Dulbecco’s medium (ATCC) supplemented with 20% fetal bovine
serum/1% penicillin–streptomycin. CLA expression on these cells
was determined by flow cytometry prior to metabolic inhibitor
studies, and cultures were maintained for p50 passages. Vibrio
cholerae neuraminidase was purchased from Roche Diagnostics,
Inc. (Indianapolis, IN). Protease bromelain, GlcNAc, and BAG were
purchased from Sigma Chemical Inc. (St Louis, MO). 4-F-GlcNAc
was synthesized and provided by the Chemical Resource Laboratory
at Roswell Park Cancer Institute (Buffalo, NY).
Cell treatments
For metabolic inhibitor treatments, exponentially growing Hut 78
cultures were incubated with non-growth inhibitory concentrations
of 4-F-GlcNAc (10-100 mM), a putative inhibitor of N-acetyllactosa-
mine synthesis), BAG (2 mM) (a metabolic inhibitor of O-glycan
biosynthesis), and GlcNAc (a molecular control). Non-toxic and
carbohydrate-modifying concentrations of 4-F-GlcNAc were chosen
based on prior experimentation with treatments of ex vivo human T
cells and concentrations of BAG were selected based on maximal
O-glycan inhibitory effects at non-growth inhibitory concentrations
as reported previously (Dimitroff et al., 2003a). Cultures were
incubated for 43-cell doublings and then harvested for analyses.
Cell viability was confirmed by Trypan blue exclusion.
For de-sialylation of cell surface glycoconjugates and removal of
all selectin ligand expression, cells were harvested, washed
twice with PBS containing Ca2þ /Mg2þ , and then incubated with
0.2 U/ml neuraminidase for 1 hour at 371C. For removal of selectin
glycoprotein ligands, T cells were incubated with 0.1% bromelain
for 1 hour at 371C as described previously (Dimitroff et al., 2003a).
Bromelain is a protease known to remove membrane proteins,
including all E-, P-, and L-selectin glycoprotein ligands expressed on
human hematopoietic and carcinomatous cells (Dimitroff et al.,
2004). Residual E-selectin ligand activity after bromelain treatment
would be indicative of activity contributed by a glycolipid
component. To confirm complete digestion with neuraminidase
and bromelain treatment, we assayed the cell surface expression of
sialyl Lewis X and PSGL-1, respectively, by flow cytometry.
Flow cytometry
Cells following inhibitor/protease treatments were washed twice
with cold PBS/2% fetal bovine serum and suspended in PBS/1% fetal
bovine serum. Rat IgM anti-sialyl Lewis X mAb HECA-452 (20 mg/ml)
(BD Biosciences Inc., San Jose, CA), mouse IgG anti-human PSGL-1
mAb PL-2 (20 mg/ml) (BD Biosciences), or mouse IgM anti-sialyl-
fucosylated core 2 O-glycan mAb CHO-131 (20 mg/ml) (Walcheck
et al., 2002), or appropriate isotype-matched control antibody (2mg/
test) was incubated with cells for 1 hour on ice as described
previously (Ferenczi et al., 2002; Dimitroff et al., 2003a). Following
two washes, cells were incubated with fluorochrome-conjugated
secondary antibody for 30 minutes on ice. After washing twice, flow
cytometry was performed using a FACScan apparatus equipped with
an argon laser tuned at 488 nm (Becton Dickinson). Cells stained
with relevant isotype control antibody were subtracted from cells
stained with test antibody to control for nonspecific binding.
Parallel-plate flow analysis
Tethering and rolling of T cells on recombinant human E- and
P-selectin-Ig chimera (R & D Systems Inc., Minneapolis, MN) were
analyzed using in the parallel-plate flow chamber under physiologic
shear stress conditions (Dimitroff et al., 2003a). For preparation
of immobilized chimera spots, E-selectin-Ig (50 ng/50 ml 0.1 M
NaHCO3, pH 9.6) or P-selectin-Ig (50 ng/50 ml 0.1 M NaHCO3, pH
9.6) was pipetted onto Ten-twenty-nineTM Petri dishes and allowed to
adsorb for 24 hours at 41C. Human IgG (500 mg/50 ml spots) were also
prepared to control for the contribution of human IgG in chimera.
After removing chimeric solution, fetal bovine serum (100%) was
then pipetted over the chimera spots and incubated for 2 hours at
371C to block nonspecific binding sites. Untreated or treated T cell
cultures as described above were washed twice in Hank’s balanced
salt solution, suspended at 2 106/ml in Hank’s balanced salt
solution /10 mM HEPES/2 mM CaCl2 (H/H/Ca
2þ ). and infused into
the chamber over chimera or human IgG spots. Cell tethering was
permitted at 0.6 Dyn/cm2 for 1 minute, then stepwise increments in
shear stress every 15 seconds were employed to a final shear stress
level of 60 Dyn/cm2. Cell rolling assessments were made at 1.5 Dyn/
cm2 from the mid-point of the chamber viewing field (4 fields/
selectin spot, three different experiments) at  200 magnification.
All experiments were observed in real time and videotaped for
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offline analysis. Negative control experiments were performed in
parallel, wherein cell binding was examined in H/H adhesion assay
medium containing 5 mM EDTA to chelate Ca2þ required for selectin
binding as well as assaying cell binding to human IgG control spots.
Cell lysate preparation, immunoprecipitation, SDS-PAGE, and
Western blotting
Cell lysates were prepared and analyzed as follows. Cells from
metabolic inhibitor/enzymatic treatments were washed 3 in ice-
cold PBS and lysed in buffer containing 150 mM NaCl, 50 mM Tris-
HCl, pH 7.4, 1 mM EDTA, 0.02% NaAzide, 20 mg/ml phenylmethyl-
sulfonyl fluoride, CompleteTM protease inhibitor tablets (Roche
Diagnostics, Inc.) and 2% NP-40 at a ratio of 250ml lysis buffer to
108 cells. Following 2 hours incubation on ice, insoluble cellular
debris was pelleted by centrifugation for 30 minutes at 10,000 r.p.m.
Solubilized protein was harvested and quantified by Bradford protein
assay (Sigma Chemical).
For immunoprecipitation of PSGL-1 or CD43, anti-human PSGL-1
mAb KPL-1 or anti-human CD43 mAb 1G10 (BD Biosciences) was
added to cell lysates pre-cleared in recombinant protein G-agarose
(Invitrogen, Inc., Carlsbad, CA) at a ratio of 2 mg Ab to 100 mg lysate
for 18 hours at 41C on a rotator. Immunoprecipitations with mouse
IgG isotype control at a similar Ab:lysate ratio were also performed
to serve as negative controls. The antibody–lysate mixture was then
added to protein G-agarose, which was pre-washed with lysis buffer/
2% NP-40/1% SDS/1% BSA, and incubated for42 hours at 41C on a
rotator. The antibody–lysate–protein G-agarose mixtures were spun
down, supernatants were removed, and immunoprecipitates were
washed 3 with lysis buffer/2% NP-40/1% SDS/1% BSA and then
twice with lysis buffer/2% NP-40.
For SDS-PAGE and Western blotting, total cell lysates or
immunoprecipitates were diluted and boiled in reducing sample
buffer, and separated on 4–20% gradient SDS-PAGE gels. Resolved
protein was transferred to ImmunoblotTM PVDF membrane (Bio-Rad
Inc., Hercules, CA) and blocked with fetal bovine serum for 1 hour at
room temperature. Blots were incubated with anti-human CLA mAb
HECA-452 (1mg/ml), anti-human PSGL-1 mAb KPL-1 (1mg/ml),
mouse E-selectin-human Ig chimera, anti-sialyl-fucosylated core 2
O-glycan mAb CHO-131 (1mg/ml), anti-human CD43 mAb 1G10,
or mouse IgG anti-human CD43 mAb L60 (1 mg/ml) for 1 hour at
room temperature. Isotype control immunoblots using either rat IgM,
human IgG, mouse IgM, or mouse IgG were performed in parallel to
control for primary antibody specificity. After three washes with Tris-
buffered saline/0.1%Tween-20 (10 minutes/wash), blots were incu-
bated with alkaline phosphate-conjugated goat anti-rat IgM (1:400),
rat anti-mouse IgM (1:1000), goat anti-human IgG (1:1000), or goat
anti-mouse IgG (1:5000). Alkaline phosphate substrate, Western
Blues (Promega, Madison, WI) was then added to develop blots.
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